SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

BACKGROUND: Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons in Qatar. METHODS: All SARS-CoV-2 antibody-positive persons from April 16...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:EClinicalMedicine
Egile Nagusiak: Abu-Raddad, Laith J., Chemaitelly, Hiam, Coyle, Peter, Malek, Joel A., Ahmed, Ayeda A., Mohamoud, Yasmin A., Younuskunju, Shameem, Ayoub, Houssein H., Al Kanaani, Zaina, Al Kuwari, Einas, Butt, Adeel A., Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Abdul Rahim, Hanan F., Nasrallah, Gheyath K., Yassine, Hadi M., Al Kuwari, Mohamed Ghaith, Al Romaihi, Hamad Eid, Al-Thani, Mohamed H., Al Khal, Abdullatif, Bertollini, Roberto
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2021
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8079668/
https://ncbi.nlm.nih.gov/pubmed/33937733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100861
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak